Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
Reviva Announces Proposed Public Offering
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]